Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial

Journal of Clinical Oncology

Volumn 24, Issue 18, 2006, Pages 2715-2722

  Van Den Bent, Martin J ^a   Carpentier, Antoine F ^b   Brandes, Alba A ^b   Sanson, Marc ^b   Taphoorn, Martin J B ^b   Bernsen, Hans J J A ^b   Frenay, Marc ^b   Tijssen, Cees C ^b   Grisold, Wolfgang ^b   Sipos, Laslo ^b   Haaxma Reiche, Hanny ^b   Kros, Johannes M ^b   Van Kouwenhoven, Mathilde C M ^b   Vecht, Charles J ^b   Allgeier, Anouk ^b   Lacombe, Denis ^b   Gorlia, Thierry ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; PCV PROTOCOL;

ADJUVANT THERAPY; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESEARCH; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OLIGODENDROGLIOMA; PHASE 3 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SKIN ALLERGY; TREATMENT OUTCOME; VOMITING; ADJUVANT CHEMOTHERAPY; BRAIN TUMOR; CHROMOSOME 1; CHROMOSOME 19; GENETICS; HETEROZYGOSITY LOSS; MIDDLE AGED; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DOSE FRACTIONATION; FEMALE; HUMANS; LOMUSTINE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROCARBAZINE; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 33745532038     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.6078     Document Type: Article

References (18)

1. Cairncross G, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12:2013-2021, 1994
2. van den Bent MJ, Kros JM, Heimans JJ, et al: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology 51:1140-1145, 1998
3. Glioma Meta-Analysis Group: Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018, 2002
4. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
5. van den Bent MJ, Looijenga LHJ, Langenberg K, et al: Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276-1284, 2003
6. International Commission on Radiation Units and Measurements: International Commission on Radiation Units and Measurements Report 50: Prescribing, Recording and Reporting Photon Beam Therapy. International Commission on Radiation Units and Measurements, Bethesda, MD, 1993, pp 1-72
7. Macdonald DR, Cascino TL, Schold SC, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
8. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
9. Smith JS, Perry A, Borell TJ, et al: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytoma, and mixed oligoastrocytomas. J Clin Oncol 18:636-645, 2000
10. Coons SW, Johnson PC, Scheithauer BW, et al: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381-1391, 1997
11. van den Bent MJ, Chinot O-L, Cairncross JG: Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-oncol 5:128-138, 2003
12. Krouwer HGJ, van Duinen SG, Kamphorst W, et al: Oligoastrocytomas: A clinicopathological study of 52 cases. J Neurooncol 33:223-238, 1997
13. Bauman GS, Ino Y, Yeki K, et al: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendroglioma, Int J Radiat Oncol Biol Phys 48:825-830, 2000
14. Cairncross JG, Seiferheld W, Shaw E, et al: An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02. J Clin Oncol 23:107, 2004 (suppl, abstr 1500)
15. Walker MD, Alexander E, Hunt WE, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial. J Neurosurg 49:333-343, 1978
16. Hegi ME, Diserens A-C, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
17. Patchell RA, Tibbs PA, Regine WF, et al: Postoperative radiotherapy in the treatment of single metastases to the brain. JAMA 280:1485-1489, 1998
18. van den Bent MJ, Afra D, De Witte O, et al: Long term results of EORTC study 22845: A randomized trial on the efficacy of early versus delayed radiation therapy of low-grade astrocytoma and oligodendroglioma in the adult. Lancet 366:985-990, 2005